Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease

Adam J de Belder, Marek W Radomski, Howard J Why, Peter J Richardson, John F Martin

Abstract

Objective—To determine the activity of the calcium-dependent constitutive (cNOS) and calcium-independent inducible nitric oxide (iNOS) synthases in heart tissue from patients with different cardiac diseases.

Patients and design—Endomyocardial biopsy specimens were obtained from patients with dilated hearts (by echocardiography and ventriculography) and normal coronary arteries (by selective angiography). Recognised clinical, radiological, and histopathological criteria were used to diagnose non-inflammatory dilated cardiomyopathy (DCM) (n = 6), inflammatory cardiomyopathy (ICM) (n = 5), and peripartum cardiomyopathy (PPCM) (n = 3). Comparative groups were chosen with similarly dilated hearts caused by ischaemic (n = 5) or valvar disease (n = 4), and, in addition, non-dilated hearts with ischaemic (n = 5) and valvar (n = 3) disease. Venous blood was taken at the time of myocardial biopsy for assay of plasma tumour necrosis factor alpha (TNFα).

Results—Myocardial tissue from patients with DCM, ICM, and PPCM showed considerable iNOS activity (16.8 (2.7) pmol citrulline/mg protein/min) with little or no cNOS activity (1.3 (0.9) pmol citrulline/mg protein/min). In contrast, myocardial tissue from patients with both dilated and non-dilated hearts of ischaemic or valvar aetiology showed cNOS and little, if any, iNOS activity (dilated—cNOS 11.7 (2.4) and iNOS 0.8 (0.6) pmol citrulline/mg protein/min; non-dilated—cNOS 12.1 (1.8) and iNOS 1.4 (0.8) pmol citrulline/mg protein/min). Plasma TNFα was detectable only in patients with inflammatory DCM.

Conclusions—These results support the hypothesis the generation of nitric oxide by iNOS accounts for some of the dilatation and impaired contractility associated with inflammatory and non-inflamamatory dilated cardiomyopathy and peripartum cardiomyopathy.

Keywords: nitric oxide; cardiomyopathy

The clinical management of patients with dilated heart muscle disease is limited to treating the consequences, rather than the causes, of the myocardial damage because the cellular and immune mechanisms underlying the pathology are poorly understood. Recent research has suggested that the myocardial generation of nitric oxide (NO) may be important in the negative inotropism associated with these conditions.

Nitric oxide is generated from L-arginine by the NO synthases. One is constitutive (cNOS), Ca2+/calmodulin and NADPH dependent, and generates NO from the endothelium. Under basal conditions the endothelial generation of NO maintains vascular tone by stimulating the soluble guanylate cyclase, thus increasing cyclic GMP in smooth muscle cells. The cNOS has been demonstrated in the endocardial endothelium and cardiac myocytes. Nitric oxide is known to have negative chronotropic and inotropic effects in several in vitro cardiac preparations.

A further enzyme that generates NO requires appropriate cytokines for its de novo gene transcription. This so-called inducible NO synthase (iNOS) has been purified and cloned in human cells and generates large quantities of NO. The systemic generation of NO by this enzyme in the vasculature accounts for the profound decrease in peripheral tone and the resistance to vasoconstrictors that occurs in endotoxaemia. Inhibitors of NO synthesis have proved to be beneficial in patients with septic shock. However, it is apparent that under certain inflammatory conditions in various tissues, local NO generation by the iNOS has important physiological and pathophysiological effects. Indeed, cultured endocardial cells and myocytes express the iNOS after endotoxaemic and cytokine challenge, and NO generated by this pathway has profound negative inotropic effects in several animal myocardial preparations. Thus the
impaired cardiac function seen with different inflammatory heart muscle disorders, such as endotoxaemia, acute myocarditis, heart transplant rejection, postpartum cardiomyopathy, interleukin-induced cardiomyopathy, and dilated cardiomyopathy (DCM) may be due to increased NO generation by this enzyme. In support of this hypothesis, we showed the presence of the iNOS in ventricular tissue from patients with DCM. To determine whether this enzyme is present in other heart conditions, we determined the NO synthase activities in ventricular tissue obtained from non-dilated hearts (ischaemic heart disease and aortic stenosis) and dilated hearts (non-inflammatory and inflammatory dilated cardiomyopathy, peripartum cardiomyopathy, aortic regurgitation, and ischaemic cardiomyopathy).

**Patients and methods**

This investigation was approved by the King’s College Hospital ethics committee. All patients gave informed consent for this investigation.

**PATIENTS**

All patients underwent transthoracic echocardiography, using a Hewlett Packard 1500 Sonos system with a 2-5 MHz phased array transducer. Left ventricular dimensions were measured from the left parasternal edge in the long axis.

**DILATED HEARTS**

*Non-inflammatory dilated cardiomyopathy* was diagnosed in six patients with clinical evidence of heart failure, dilated hearts on echocardiography, normal coronary arteries on selective angiography, and the absence of specific heart muscle disorder on histological examination of an endomyocardial biopsy specimen.

*Inflammatory dilated cardiomyopathy* was diagnosed in five patients in heart failure with dilated hearts and normal coronary arteries. Endomyocardial biopsy specimens from patients in this group were not examined by specific immunohistochemical staining. A cardiac pathologist made the distinction between inflammatory and non-inflammatory disease based on histological examination for areas of lymphocytic infiltration, interstitial widening with an increase in interstitial fibrous tissue, and little or no necrosis.

*Peripartum cardiomyopathy* was defined as heart failure that developed in the last month of pregnancy or within the first five postpartum months for which there was no other determinable cause or cardiac disease. The three patients in this group developed severe cardiac failure, one month, two months, and five months after delivery. Right ventricular endomyocardial biopsy specimens were obtained at cardiac catheterisation.

*Ischaemic dilated cardiomyopathy* (n = 5) was defined as heart failure in the presence of a dilated myocardium with occlusive coronary artery disease sufficient to account for the impaired cardiac dysfunction. Endomyocardial biopsy specimens of the right ventricle were taken at the time of cardiac catheterisation.

**Aortic regurgitation** (n = 4) was defined as heart failure caused by grade III/IV aortic valve regurgitation (as defined by echocardiography and ventriculography) in the presence of normal coronary arteries. Right ventricular Trucut biopsy specimens were obtained at the time of valve replacement.

**NON-DILATED HEARTS**

*Aortic stenosis* (n = 2) was defined as symptoms of chest pain or syncope with a calcified aortic valve with echocardiographic and catheter evidence of a gradient of >80 mm Hg across the valve and normal coronary arteries. Right ventricular Trucut biopsy specimens were obtained at the time of valve replacement.

*Non-dilated ischaemic hearts* (n = 5).—Right ventricular Trucut biopsies were obtained from patients undergoing coronary bypass surgery who had normal ventricular function on echocardiography and ventriculography.

**BIOCHEMISTRY**

All myocardial tissue was snap frozen in liquid nitrogen at biopsy and stored at −70°C. Tissue was freeze-crushed and homogenised in ice cold buffer, then centrifuged at 20 000 g for 20 min. The soluble fraction was used to measure the constitutive and inducible (in the presence of 1 mmol ethylene glycol tetraacetic acid) activity of NO synthase, by using the conversion of 14C-L-arginine to 14C-L-citrulline, as previously described (detection limit <0.1 pmol citrulline/mg protein/min). 21

**CYTOKINE MEASUREMENTS**

Venous blood was collected at the time of cardiac catheterisation from the antecubital fossa. Plasma was stored at −20°C until immunoassay (Amersham, UK) for tumour necrosis factor (TNFα).

**STATISTICAL ANALYSIS**

Results are presented as means (SEM), and results are compared by analysis of variance (ANOVA). P < 0.05 is regarded as statistically significant.

**Results**

**ECOCARDIOGRAPHIC AND VENTRICULOGRAPHIC DATA**

Patients were selected for the study if they fitted the diagnostic criteria above. The table shows the echocardiographic and ventriculographic data on the cardiac dimensions for the different groups. There were no significant differences in left ventricular dimensions between the groups with dilated hearts.

**NITRIC OXIDE SYNTHASE ASSAY**

Patients with dilated cardiomyopathy (inflammatory and non-inflammatory) and peripartum cardiomyopathy expressed iNOS (16-8 (2-7) pmol citrulline/mg/protein/min) with little or no cNOS activity (1·3 (0-9) pmol citrulline/mg/protein/min). There was no sig-
Myocardial tissue from patients with dilated hearts of non-ischaemic origin (inflammatory) expressed inducible nitric oxide synthase (iNOS) with little or no constitutive nitric oxide synthase (cNOS). In contrast, myocardial tissue from patients with dilatation of ischaemic or valvar origin showed significant cNOS activity with little or no iNOS activity. This distribution of enzyme activity was similar in myocardial tissue from patients with non-dilated hearts with ischaemic or valvar disease.

![Graph showing characteristics, echocardiographic dimensions, and New York Heart Association classification of dyspnoea for each group of patients](image)

**Table:**

<table>
<thead>
<tr>
<th>Data</th>
<th>Inflammatory</th>
<th>Ischaemic or valve disease</th>
<th>Non-dilated</th>
</tr>
</thead>
<tbody>
<tr>
<td>No (M/F)</td>
<td>14 (9/5)</td>
<td>9 (6/3)</td>
<td>8 (6/2)</td>
</tr>
<tr>
<td>Age</td>
<td>48 (12)</td>
<td>42 (14)</td>
<td>52 (16)</td>
</tr>
<tr>
<td>Echo dimensions:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEDD (cm)</td>
<td>7-0 (0-6)</td>
<td>6-6 (0-5)</td>
<td>4-6 (0-5)</td>
</tr>
<tr>
<td>LVESD (cm)</td>
<td>6-0 (0-5)</td>
<td>5-4 (0-6)</td>
<td>3-1 (0-8)</td>
</tr>
<tr>
<td>NYHA:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>II</td>
<td>2</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>III</td>
<td>8</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>IV</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Infarctive dilated: includes patients with dilated cardiomyopathy (non-inflammatory and inflammatory) and peripartum cardiomyopathy; Non-dilated, includes patients with non-dilated hearts and ischaemic or valvar heart disease. LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter.

A significant difference of iNOS activity between the three patient groups. In contrast, patients with dilatation of ischaemic or valvar origin showed significant cNOS (11-7 (2-4) pmol citrulline/mg protein/min) activity with little, if any, iNOS (0-8 (0-6) pmol citrulline/mg protein/min) activity. Myocardial tissue from patients with non-dilated heart disease had distributions of enzyme activities (cNOS 12-1 (1-8), iNOS 1-4 (0-8) pmol citrulline/mg protein/min) similar to those in patients with dilatation caused by ischaemic or valve disease (figure).

**Cytokine Results**

Patients with histological evidence of inflammatory cardiomyopathy (n = 8) had detectable plasma concentrations of TNFa (2-76 (1-62) ng/ml). In all other patients with dilated or non-dilated hearts (n = 18) plasma concentrations of TNFa were below the detectable range.

**Discussion**

Several pathogenetic mechanisms lead to myocardial dilatation. Coronary artery occlusion leads to widespread myocyte necrosis, with subsequent scarring and thinning of the affected part of the ventricle, and left ventricular dilatation in chronic aortic valve regurgitation is caused by longstanding left ventricular volume overload. However, in several myocardial disorders that are associated with cardiac dilatation and impaired function the pathophysiological events leading to dilatation are less clear. These include dilated cardiomyopathy, acute myocarditis, peripartum cardiomyopathy, interleukin-induced cardiomyopathy, heart transplant rejection, AIDS-related cardiomyopathy, and endoxanxemia. The histological appearances of these heart muscle disorders range from an intense inflammatory infiltrate with myocytolysis (acute myocarditis and severe cardiac transplant rejection) to essentially normal myocyte appearances, with a minor or relative lack of inflammatory cells (dilated cardiomyopathy). While the former could be explained (at least in part) by cytotoxicity mediated by T cells, the latter suggests that there must be other factors involved causing dilated impaired hearts.

Our results show that in patients with severely impaired cardiac function with a diagnosis of inflammatory and non-inflammatory dilated cardiomyopathy and peripartum cardiomyopathy there is significant expression of iNOS and low cNOS activity. In similarly dilated hearts where dilatation is of ischaemic or valvar origin expression of iNOS is very low and expression of cNOS is high. Furthermore, in non-dilated hearts where there is ischaemic or valvar disease most of the NO generation is the result of activity of the cNOS.

In addition, our results show that in patients with evidence of an inflammatory process within the myocardium, there is an increase in plasma TNFa. Some cytokines, such as interleukin-1β (IL-1β), interleukin-2 (IL-2), TNFa, and interferon-γ (IFN-γ), are negatively inotropic in several in vitro cardiac preparations. The clinical use of some of these factors, such as IL-2 and IFNγ, for chemotherapy, is limited by the development of a cardiomyopathy. Recent animal work has linked the negative inotropic effect of these cytokines to increased NO generation, and the results confirm the effect of NO biosynthesis improved the cytokine-induced depression of cardiac function. Our observations have now provided a link between the release of TNFa, the expression of iNOS, and myocardial dilatation caused by myocardial inflammation.

The aetiology of DCM remains unknown. There is some evidence, by no means conclusive, that persistence of enteroviral activity has an aetiological link. Autoantibodies against normal and abnormal cardiac tissue have also been described. These two theories are not exclusive; because viral infection can lead to autoimmunity. Our results confirm our previous findings of the presence of the iNOS in heart tissue from patients with dilated cardiomyopathy. Whether this enzyme is present as a result of a viral and/or autoimmune trigger is a source of continued debate. It is interesting to speculate whether viral infection leads to induction of the iNOS in myocardial tissue as do some neurotropic viruses in the brain.
Heart failure in association with pregnancy was first recognised in 1849, and a primary heart muscle disease related to late pregnancy and the puerperium was described in 1870. In our patients who had peripartum cardiomyopathy, there was histological evidence of an inflammatory process in hypertrophied, dilated hearts, with thickening of the endocardium. Our results show that there is induction of the iNOS in right ventricular tissue of these patients, suggesting that NO generation by this enzyme may account for some of the impaired cardiac performance seen in this condition. It may be that NO is the postpartum factor present in peripartum cardiomyopathy, as suggested by Mussner in 1938.

The NO synthase activities, whether Ca++-dependent or independent, were similar. Under normal conditions, there is close physiological regulation of intracellular Ca++ with each myocardial contraction cycle. However, when the Ca++-independent iNOS is expressed, there is no regulatory mechanism to control NO generation; and therefore there will be a much longer net increase of NO over time, regardless of the level of intramyocyte Ca++. Thus although under assay conditions the amounts of enzyme produced may be similar, the effect of iNOS expression in vivo may be quite different.

The generation of NO by iNOS in the myocardium may exert a negative inotropic effect by two mechanisms. One is by stimulation of the soluble guanylate cyclase with an increase in cyclic GMP, which is known to have a negative inotropic effect in several heart preparations. Interestingly, we have previously shown a rise in Ca++-independent cyclic GMP in myocardium from patients with DCM. The other mechanism is a direct inhibitory effect of NO on Fe-S-containing enzymes of mitochondrial respiration, which would affect myocardial ATP production, as has been shown in cultured aortic smooth muscle cells.

We found that in heart tissue where there was increased iNOS activity there was also a decrease in CNOS activity. There is growing evidence that these reciprocal interactions between iNOS and CNOS take place in other cells such as bovine aortic endothelial cells and human umbilical vein cells and may reflect a regulation of enzyme activities by cytokines, which increase the rate of CNOS mRNA degradation.

Our studies did not determine the source of the NOS activity within the endomyocardial tissue. The presence of CNOS has been demonstrated in myocytes and endocardial cells in vitro and it is possible that neuronal NOs may contribute to this activity. Under the appropriate cytokine conditions cultured myocytes, endocardial cells, and white cells all have the capacity to express iNOS. Further immunological studies with in situ hybridisation will resolve this issue.

Animal studies have shown that the negative inotropic inducible NO synthase (iNOS) expression could be ameliorated by the pharmacological inhibition of NO synthase activity. These results suggest that inhibition of NO synthase could be used to treat the negative inotropic effects associated with dilated hearts of inflammatory aetiology. However, the lack of selective inhibitors of iNOS seems to be an obstacle to the implementation of this approach. NO synthase inhibitors available to date are not selective and also interfere with the activity of CNOS in myocardium, endothelium, and platelets. This may lead to decreased blood flow, increased blood cell reactivity, and changes in myocardial contractility. However, development of selective inhibitors of the iNOS may provide a novel treatment for inflammatory heart disease.


